CSP exam testspecialty pharmacyWith CORRECT

• | Page

CSP exam test(specialty pharmacy)With CORRECT ANSWERs!!PDC calculation PDC = (# of unique days with supply / number of days in a period) x 100

Question 1: Which medication is a Jak inhibitor?

• Humira (adalimumab)
• Orencia (abatacept)
• Actemra (toclizumab)
• Xeljanz (tofacitinib)

CORRECT ANSWER : d. Xeljanz (tofacitinib)

Question 2: Which medication can elevate cholesterol?

• Actemra (toclizumab)
• Enbrel (etanercept)
• Simponi (golimumab)
• Kineret (anakinra)

CORRECT ANSWER : a. Actemra (toclizumab)

• | Page

Question 3: Which shingles vaccine is safe to administer with

TNF inhibitors?

• Adacel
• Zostavax
• Shingrix
• Varivax

CORRECT ANSWER : c. Shingrix

Question 4: Most biologics increase the risk of infections, which

of the following also increases the risk of neutropenia?

• Rituxin (rituximab)
• Taltz (ixekizumab)
• Remicade (infliximab)
• Cimzia (certolizumab pegol)

CORRECT ANSWER : b. Taltz (ixekizumab)

Question 5: Which psoriasis medication does not require

screening for tuberculosis?

• | Page

• Stelara (ustekinumab)
• Otezla (apremilast)
• Cocentyx (seculinumab)
• Humira (adalimumab)

CORRECT ANSWER : b. Otezla (apremilast)

Question 6: What is the standard starting dose for Taltz

(ixekizumab) when used to treat psoriatic arthritis?

• 160mg subcutaneously once, followed by 80mg

subcutaneously at weeks 2, 4, 6, 8, 10 and 12; then 80mg subcutaneously every 4 weeks

• 160mg subcutaneously once, followed by 80mg

subcutaneously every 4 weeks

• 160mg subcutaneously once, followed by 80mg

subcutaneously every week for 4 weeks, then 80mg every 4 weeks

• 160mg subcutaneously once, followed by 80mg

subcutaneously every other week

• | Page

CORRECT ANSWER : b. 160mg subcutaneously once,

followed by 80mg subcutaneously every 4 weeks

Question 7: A 45 y/o, 200lb patient is struggling with severe

dermatitis and the provider wants to potentially start a biologic.Which medication would you recommend?

• Protopic (tacrolimus)
• Humira (adalimumab)
• Stelara (ustekinumab)
• Dupixent (dupilumab)

CORRECT ANSWER : d. Dupixent (dupilumab)

Question 8: A 56 y/o, 140lb patient with psoriasis will be

starting Stelara (ustekinumab), but the provider wants to verify the dosing of the medication. What starting dose would you recommend?

• Inject 45 mg subcutaneously at weeks 0 and 4, followed by 45

mg every 12 weeks

• Inject 90 mg subcutaneously at weeks 0 and 4, followed by 90

mg every 12 weeks